

Basic research in renal tumours: Looking for the right treatment for the right patient

Poster Session 10

Saturday, 12 March
14:15 - 15:45

Location: Room 14c (ICM, Level 1)

Chairs: T. Klatte, Vienna (AT)
I. Mincik, Presov (SK)
G. Stewart, Cambridge (GB)

Aims and objectives of this presentation

To explore the molecular mechanism of resistance of the different drugs available to treat advanced RCC as well as to select patients sensitive or resistant to the different drugs.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 110 **Combination therapy using molecular-targeted drugs inhibiting platelet-derived growth factor receptors in the tumor microenvironment of renal cell carcinoma**
By: [Kitano H.](#)¹, Teishima J.¹, Yuge R.², Shinmei S.¹, Nagamatsu H.¹, Goto K.³, Syoji K.¹, Inoue S.¹, Hayashi T.¹, Sentani K.³, Kitadai Y.², Yasui W.³, Matsubara A.¹
Institutes:¹Hiroshima University, Dept. of Urology, Hiroshima, Japan, ²Hiroshima University, Dept. of Gastroenterology, Hiroshima, Japan, ³Hiroshima University, Dept. of Molecular Pathology, Hiroshima, Japan
- 111 **Netrin-1 protein responsible for disease progression in renal cell carcinoma sunitinib resistant tumors**
By: [Frees S.K.](#), Chavez-Munoz C., Zhou B., Wong A., Raven P., So A.I.
Institutes:Vancouver Prostate Centre, Dept. of Urological Sciences, Vancouver, Canada
- 112 **Acquired resistance to tyrosine kinase inhibitor sunitinib is associated with functional alterations in renal cell carcinoma cell lines**
By: [Vynnytska-Myronovska B.](#), Schendel D., Unteregger G., Stöckle M., Junker K.
Institutes:Saarland University Medical Center, Dept. of Urology, Homburg/Saar, Germany
- 113 **Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo**
By: [Imai S.](#), Tei H., Miyake H., Fujisawa M.
Institutes:Kobe University Graduate School of Medicine, Dept. of Urology, Kobe, Japan
- 114 **Clonal mTOR pathway activation as a predictive biomarker for mTOR inhibitor therapy in clear cell renal cell carcinoma**
By: [Stares M.](#)¹, Nicol D.², O'Brien T.³, Challacombe B.³, Rowan A.¹, Horswell S.⁴, Salm M.⁴, Soutati A.⁵, Hazell S.⁶, Chandra A.⁷, López J.⁸, Fisher R.⁹, Chowdhury S.⁵, Rudman S.⁵, Gore M.⁹, Matthews N.¹⁰, Fotiadis N.¹¹, Larkin J.⁹, Turajlic S.¹, Swanton C.¹
Institutes:¹The Francis Crick Institute, Translational Cancer Therapeutics Laboratory, London, United Kingdom, ²The Royal Marsden Hospital NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ³Guy's and St Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁴The Francis Crick Institute, Bioinformatics and Biostatistics, London, United Kingdom, ⁵Guy's and St Thomas' NHS Foundation Trust, Dept. of Medicine, London, United Kingdom, ⁶The Royal Marsden Hospital NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, ⁷Guy's and St Thomas' NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, ⁸Cruces University Hospital, Dept. of Pathology, Bilbao, Spain, ⁹The Royal Marsden Hospital NHS Foundation Trust, Dept. of Medicine, London, United Kingdom, ¹⁰The Francis Crick Institute, Advanced Sequencing Facility, London, United Kingdom, ¹¹The Royal Marsden Hospital NHS

Foundation Trust, Dept. of Interventional Radiology, London, United Kingdom

- 115 **CMG-101: Novel selective mTOR 1/2 inhibitor for renal cell carcinoma**
By: Park D.S., Seo J.B., Lee S.R., Hong Y.K., Hong J.Y., Choi K.H.
Institutes:Cha University, Dept. of Urology, Seongnam, South Korea
- 116 **Acceleration of proteinuria without significant impact on renal function and its protection by angiotensin II receptor blocker in rats treated with axitinib**
By: Imai S., Miyake H., Fujisawa M.
Institutes:Kobe University Graduate School Of Medicine, Dept. of Urology, Kobe, Japan
- 117 **Predicting clinical response based on ex vivo drug treatment in renal cell carcinoma using kinase activity profiling**
By: Oosterwijk-Wakka J.¹, Ruijtenbeek R.², Houkes L.², Mulders P.¹, Oosterwijk E.¹
Institutes:¹Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, ²Pamgene International, Research & Development, 's Hertogenbosch, The Netherlands
- 118 **Patient-derived avatar mouse models predicts prognosis in advanced renal cell carcinoma**
By: Trilla E.¹, Regis L.¹, Lorente D.¹, Servián P.¹, Celma A.¹, Salvador C.¹, Planas J.¹, Placer J.¹, Suarez C.², Martinez M.², Jimenez-Valerio G.², Detorres I.³, Morales R.², Jimenez J.⁴, Vivancos A.⁴, Nuciforo P.⁵, Carles J.², Casanovas O.⁵, Morote J.¹
Institutes:¹Hospital Universitari Vall d'Hebron, Dept. of Urology, Barcelona, Spain, ²Hospital Universitari Vall d'Hebron, Dept. of Oncology, Barcelona, Spain, ³Hospital Universitari Vall d'Hebron, Dept. of Pathology, Barcelona, Spain, ⁴Vall D'Hebron Institute of Oncology, Cancer Genomic Group, Barcelona, Spain, ⁵Vall D'Hebron Institute of Oncology, Molecular Pathology Group, Barcelona, Spain
- 119 **Interleukin-22 (IL-22), a T-cell secreted cytokine, contributes to renal cell carcinoma (RCC) progression and is associated with poor outcome in RCC patients**
By: Rodler S.², Shangqing S.³, Weidenbusch M.², Staehler M.⁵, Seliger B.⁴, Stief C.G.⁵, Anders H-J.², Nuhn P.¹
Institutes:¹University Medical Centre Mannheim, University of Heidelberg, Dept. of Urology, Mannheim, Germany, ²Klinikum Universität München, Nephrologisches Zentrum, Medizinische Klinik Und Poliklinik IV, Munich, Germany, ³Klinikum Der Universität München, Nephrologisches Zentrum, Medizinische Klinik Und Poliklinik IV, Munich, Germany, ⁴Martin-Luther-University Halle-Wittenberg Institute of Medical Immunology, Institute of Medical Immunology, Halle, Germany, ⁵Klinikum Universität München, Dept. of Urology, Munich, Germany
- 120 **The Mediator complex subunit MED8 is implicated in the progression of papillary renal cell carcinoma**
By: Syring L.¹, Klümper N.², Shaikhibrahim Z.², Offermann A.², Braun M.², Deng M.², Böhm D.², Queisser A.², Von Mässenhausen A.², Ellinger J.³, Müller S.³, Perner S.⁴
Institutes:¹University Hospital of Bonn, Dept. of Urology and Pediatric Urology; Dept. of Prostate Cancer Research, Institute of Pathology, Bonn, Germany, ²University Hospital of Bonn, Dept. of Prostate Cancer Research, Institute of Pathology, Bonn, Germany, ³University Hospital of Bonn, Clinic For Urology and Pediatric Urology, Bonn, Germany, ⁴University Hospital of Bonn, Department of Prostate Cancer Research, Institute of Pathology; Pathology Network of The University Hospital of Luebeck and Leibniz Research Center Borstel, Bonn, Germany
- 121 **TSPAN8 expression in renal cell carcinoma is a poor prognostic factor and a novel therapeutic target**
By: Hayashi T.¹, Sentani K.², Black P.³, Goto K.¹, Shinmei S.¹, Anami K.², Oo H.Z.², Teishima J.¹, Yasui W.², Matsubara A.¹
Institutes:¹Hiroshima University, Dept. of Urology, Hiroshima, Japan, ²Hiroshima University, Dept. of Molecular Pathology, Hiroshima, Japan, ³Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada
- 122 **Ritonavir and delanzomib inhibit renal cancer growth in vitro and in vivo by inducing endoplasmic**

reticulum stress synergistically

By: Isono M.¹, Sato A.¹, Asano T.¹, Okubo K.¹, Ito K.¹, Schulz W.², Asano T.¹

Institutes:¹National Defense Medical College, Dept. of Urology, Tokorozawa, Japan, ²Heinrich Heine University, Dept. of Urology, Düsseldorf, Germany

123

Experimental imaging in orthotopic xenograft models of renal cell carcinoma: Comparative evaluation of high-resolution ultrasonography, in-vivo micro-CT and 9.4T MRI

By: Linxweiler J.¹, Körbel C.², Müller A.³, Jung V.¹, Jüngel E.⁴, Siemer S.¹, Junker K.¹, Menger M.D.², Saar M.¹

Institutes:¹Saarland University Medical Center, Dept. of Urology, Homburg/Saar, Germany, ²Saarland University Medical Center, Dept. of Clinical-Experimental Surgery, Homburg/Saar, Germany, ³Saarland University Medical Center, Dept. of Diagnostic and Interventional Radiology, Homburg/Saar, Germany, ⁴Frankfurt University Medical Center, Dept. of Urology, Frankfurt am Main, Germany